Revised Press Relase for the Quarter ended 31st December, 2025

Sanjivani Paranteral Ltd reported a strong Q3FY26 with standalone revenue from operations rising 20.25% YoY to Rs. 208.63 mn, driven by 153.5% YoY growth in the Oral segment. Standalone EBITDA margin expanded to 18.62% (vs 16.5% in Q3FY25) and PAT grew 37.8% YoY to Rs. 26.16 mn. On the consolidated side, revenue grew 27.17% YoY to Rs. 220.6 mn and PAT rose 46.2% YoY to Rs. 27.76 mn, aided by the first-time contribution from the newly acquired SPL Infusion Pvt. Ltd., Pune facility. For 9MFY26, standalone revenue grew 4.5% YoY to Rs. 542.5 mn with PAT up 1.3% YoY at Rs. 59.8 mn, while consolidated revenue grew 6.81% YoY to Rs. 554.5 mn. Exports continue to dominate, accounting for about 77% of total revenue, mainly from CIS, Middle East, Africa, and Latin America markets.